| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/07/2014 | US8623853 Treatment of cancers characterized by chromosomal rearrangement of the NUT gene |
| 01/07/2014 | US8623835 Materials and methods for treatment of respiratory allergic diseases |
| 01/07/2014 | US8623833 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 01/07/2014 | US8623832 Peptide compositions that bind TLR-4 |
| 01/07/2014 | US8623831 Nuclear factor κB inducing factor |
| 01/07/2014 | US8623830 Compositions containing α-1-antitrypsin and methods for use |
| 01/07/2014 | US8623829 Peptide vaccines for cancers expressing tumor-associated antigens |
| 01/07/2014 | US8623827 Myelin basic protein peptide composition |
| 01/07/2014 | US8623825 Edible fat composition for enhancing bone strength |
| 01/07/2014 | US8623824 VIII factors for the treatment of type A hemophilia |
| 01/07/2014 | US8623823 Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist |
| 01/07/2014 | US8623821 Zymogen activators |
| 01/07/2014 | US8623820 FGF-9 and its use relating to blood vessels |
| 01/07/2014 | US8623818 Glucagon receptor antagonists, compositions, and methods for their use |
| 01/07/2014 | US8623817 Method of treating diabetes type 2 by administering ultrarapid acting insulin |
| 01/07/2014 | US8623816 Compositions and methods for treating malaria with cupredoxin and cytochrome |
| 01/07/2014 | US8623815 TRIM5alpha mutants and uses thereof |
| 01/07/2014 | US8623814 Antiviral agents |
| 01/07/2014 | US8623812 Cross-linkable glycoproteins and methods of making the same |
| 01/07/2014 | US8623811 Antimicrobial peptide, compositions, and methods of use |
| 01/07/2014 | US8623810 Protease for wound conditioning and skin care |
| 01/07/2014 | US8623643 Antisense oligonucleotide modulation of STAT3 expression |
| 01/07/2014 | US8623609 Proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents |
| 01/07/2014 | US8623419 Technology for preparation of macromolecular microspheres |
| 01/07/2014 | US8623398 Method for generating connective tissue by implanting a biodegradable silk fabric |
| 01/07/2014 | US8623393 Biomatrix structural containment and fixation systems and methods of use thereof |
| 01/07/2014 | US8623385 Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein |
| 01/07/2014 | US8623383 Recombinant antigens for diagnosis and prevention of spotted fever rickettsiae |
| 01/07/2014 | US8623380 Acellular pertussis vaccine with diphthriae- and tetanus-toxoids |
| 01/07/2014 | US8623374 Method for enhancing immune response with peptide |
| 01/07/2014 | US8623356 Demibodies: dimerization-activated therapeutic agents |
| 01/07/2014 | US8623352 Stabilized liquid and lyophilized ADAMTS13 formulations |
| 01/07/2014 | US8623351 Compositions comprising vascular and myocyte progenitor cells and methods of their use |
| 01/07/2014 | US8623348 Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP) |
| 01/07/2014 | US8623347 Antiviral drugs for treatment of arenavirus infection |
| 01/07/2014 | US8623345 Terminally-functionalized conjugates and uses thereof |
| 01/07/2014 | US8623335 Scar and rosacea and other skin care treatment composition and method |
| 01/07/2014 | US8623326 Ghrelin analogues |
| 01/07/2014 | CA2810334C Methods and compositions relating to coagulation assays |
| 01/07/2014 | CA2665958C High affinity binding site of hgfr and methods for identification of antagonists thereof |
| 01/07/2014 | CA2664915C Pharmaceutical composition comprising phenylamidine derivative and method of using the pharmaceutical composition in combination with antifungal agent |
| 01/07/2014 | CA2656604C Injectable formulation of antibiotic and solution for intravenous administration thereof |
| 01/07/2014 | CA2587361C Peptidomimetic polymers for antifouling surfaces |
| 01/07/2014 | CA2570407C Methods and compositions for modulating stem cell growth and differentiation |
| 01/07/2014 | CA2563117C Treatment of type 1 diabetes with inhibitors of macrophage migration inhibitory factor |
| 01/07/2014 | CA2546675C Pharmaceutical formulations for the sustained release of one or more active principles and applications thereof, such as therapeutic applications |
| 01/07/2014 | CA2492472C Use of urease for inhibiting cancer cell growth |
| 01/07/2014 | CA2461372C Dna sequences for human angiogenesis genes |
| 01/07/2014 | CA2453967C Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/07/2014 | CA2427896C Carrier vectors through an epithelium with tight junctions |
| 01/07/2014 | CA2413141C Peptides with wound healing activity |
| 01/07/2014 | CA2286798C Alpha-o-linked glycoconjugates with clustered(2,6)-st epitopes, methods of preparation and uses thereof |
| 01/03/2014 | WO2014005107A2 Microparticle formulations for delivery to the upper and central respiratory tract and methods of manufacture |
| 01/03/2014 | WO2014005103A2 Microparticle formulations for delivery to the lower and central respiratory tract and methods of manufacture |
| 01/03/2014 | WO2014004934A2 Compositions and methods of treating alzheimer's disease |
| 01/03/2014 | WO2014004866A1 Combinations of modalities for the treatment of diabetes |
| 01/03/2014 | WO2014004857A1 Ctla4 fusion proteins for the treatment of diabetes |
| 01/03/2014 | WO2014004692A1 Compositions and methods for treatment vitiligo |
| 01/03/2014 | WO2014004467A1 Selective cartilage therapy |
| 01/03/2014 | WO2014004465A1 Targeted therapeutics |
| 01/03/2014 | WO2014004378A1 Ompa and asp14 in vaccine compositions and as diagnostic targets |
| 01/03/2014 | WO2014004278A1 Photocleavable drug conjugates |
| 01/03/2014 | WO2014003744A1 Anti-cxcl9, anti-cxcl 10, anti-cxcl 11, anti-cxcl 13, anti-cxcr3 and anti-cxcr5 agents for inflammatory disorder |
| 01/03/2014 | WO2014003553A1 Combination for treating an inflammatory disorder |
| 01/03/2014 | WO2014003538A1 Rapid specific pathogen free animal |
| 01/03/2014 | WO2014003537A1 Anticancer treatment |
| 01/03/2014 | WO2014003536A1 Dosage regime of fusion compounds |
| 01/03/2014 | WO2014003531A1 Nasal vaccine against the development of atherosclerosis disease and fatty liver |
| 01/03/2014 | WO2014003222A1 Method for isolating the active component of bee venom |
| 01/03/2014 | WO2014003008A1 Novel histamine liberator contained in human sweat |
| 01/03/2014 | WO2014002836A1 Egfr-binding peptide |
| 01/03/2014 | WO2014002571A1 Angiotensin-converting-enzyme inhibiting dipeptide |
| 01/03/2014 | WO2014002089A1 Peptides derived from hiv gp41 for treating t-cell mediated pathologies |
| 01/03/2014 | WO2014002038A1 The use of ret agonist molecules for haematopoietic stem cell expansion protocols and transplantation therapy and a ret agonist kit |
| 01/03/2014 | WO2014001904A1 Biodegradable drug delivery for hydrophobic compositions |
| 01/03/2014 | WO2014001820A1 Japanese cedar peptide for preventing or treating allergy |
| 01/03/2014 | WO2014001749A1 Formulation comprising crh and alpha - 2 - immunoglobulin |
| 01/03/2014 | WO2014001444A1 Dosing instructions for endotoxin-binding lipopeptides |
| 01/03/2014 | WO2014001177A1 Pharmaceutical composition for treatment of the pulmonary form of altitude sickness caused by lack of oxygen and reduced air pressure |
| 01/03/2014 | WO2014000058A1 Method of treating glucose metabolism disorders |
| 01/03/2014 | WO2014000042A1 COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS |
| 01/03/2014 | WO2014000027A1 Prevention and treatment of haematological conditions |
| 01/03/2014 | WO2013167750A3 Method for diagnosis and treatment of prolactin associated disorders |
| 01/03/2014 | WO2012170930A9 Lipid nanoparticle compositions and methods for mrna delivery |
| 01/03/2014 | WO2012168680A8 Pharmaceutical preparation comprising recombinant fsh |
| 01/03/2014 | WO2012166626A8 Reagents and methods for treating dental disease |
| 01/03/2014 | WO2012158952A8 Treatment of intervertebral disc degeneration using human umbilical cord tissue-derived cells and hydrogel |
| 01/03/2014 | WO2012143845A3 New cosmetic and therapeutical uses of ghk tripeptide |
| 01/03/2014 | CA2877986A1 Ctla4 fusion proteins for the treatment of diabetes |
| 01/03/2014 | CA2877906A1 Combinations of modalities for the treatment of diabetes |
| 01/03/2014 | CA2877886A1 Targeted therapeutics |
| 01/03/2014 | CA2877562A1 Formulation comprising crh and alpha-2-immunoglobulin |
| 01/03/2014 | CA2877517A1 Purification of iduronate-2-sulfatase |
| 01/03/2014 | CA2877492A1 Method of producing recombinant iduronate-2-sulfatase |
| 01/03/2014 | CA2877272A1 Dosage regime of fusion compounds |
| 01/03/2014 | CA2876293A1 Combination for treating an inflammatory disorder |
| 01/03/2014 | CA2875749A1 Pharmaceutical composition for treatment of the pulmonary form of altitude sickness caused by lack of oxygen and reduced air pressure |
| 01/02/2014 | US20140005257 Methods of gene therapy for treating disorders of the ear by administering a vector encoding an atonal-associated factor |
| 01/02/2014 | US20140005128 Treatments of gastrointestinal disorders |
| 01/02/2014 | US20140005127 Methods of treating muscular wasting diseases using nf-kb activation inhibitors |